THERAPEUTIC EFFECT OF A UNANI FORMULATION ON HBsAg IN CHRONIC HEPATITIS B: A CASE SERIES
Objectives: Chronic hepatitis B (CHB) is a major health concern in terms of its high prevalence, as well as restricted, and costly health care resources
in India. The physicians of the Unani system of Medicine have been treating hepatitis since centuries. The purpose of our study was to assess the effect
of Unani Formulation in the treatment naÃ¯ve, CHB cases and to collect data to warrant further clinical trials.
Methods: We conducted a case series with five patient of CHB, subsequently treated with the Unani formulation. Cases were confirmed with standard
hepatitis antigen and viral measurements. The patients were treated for 6 months with measurement of the hepatitis B surface antigen (HbsAg).
Results: Loss of surface antigen occurred in the patients and became HbsAg negative within an average 13 weeks of treatment.
Discussion: We reviewed the literature related to the Unani formulation used for the treatment in this study. Its constituents have exhibited antiviral,
anti-inflammatory, immunomodulatory, hepatoprotective and antioxidant properties, suggesting possible mechanisms of action in the CHB.
Conclusion: The preliminary findings indicate the potential therapeutic role of the Unani formulation in the treatment of CHB. Clinical trials based on
this Unani pharmacopeal formulation should be conducted to explore the therapeutic potential of this formulation in CHB.
Keywords: Chronic hepatitis B, Unani Medicine, Unani formulation, Complementary Medicine, Herbal antivirals, Hepatoprotective, Warme jigar, Viral
National Clinical Guideline Centre (NICE), 2013. Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young people and adult, p. 13-15, 20. [online] Available from http://www.nice.org.uk/guidance/cg165/resources/cg165-hepatitis-b-chronic-full-guideline3; [Accessed Jan 2014]
Anand AC, Puri Pankaj: Indian Guidelines and Protocols: Hepatitis B, 2012, Chapter 53, Gastroenterology; http://www.apiindia.org/medicine_update_2013/chap53.pdf.
WHO. Hepatitis B (2014). In section Global Alert and Response (GAR). [Online] Available on WHO web site.http://www.who.int/mediacentre/factsheets.fs204/en/print.html. [Accessed Jan 2014]
Grimm D, Thimme R, Blum HE. HBV life cycle & novel drug target. Hepatol Int. 2011; 5(2): 644â€“653.
Schalm SW, Janssen HLA. Treatment of HBeAg-Positive Chronic Hepatitis B with Conventional or Pegylated Interferon, Management of Patients with Viral Hepatitis, Paris, 2004. p, 246, 251, 254.
Ansari S, Siddiqui MA, Khan AA, Ahmad MA, Jabeen A, Asif M et al. Experimental models and hepatotoxic agents used to study hepatoprotective effect of traditional drugs. Int J Adv Pharmacy Med Bioallied Sci. 2014;2:67-74.
Chang TT, et al. N Engl J Med. 2006;354:1001-1010. Marcellin P, et al. N Engl J Med. 2008;359:2442-2455.
Vimalanathan S, Ignacimuthu S, Hudson JB. Medicinal plants of Tamil Nadu (Southern India) are a rich source of antiviral activities. Pharm Biol 2009Í¾47:4229.
Verma H, Patil PR, Kolhapure RM, Gopalkrishna V. Antiviral activity of the Indian medicinal plant extract, Swertia chirata against herpes simplex viruses: A study by in-vitro and molecular approach. 2008;26; 4: 322-3.
Tiwari BK, Khosa RL. Hepatoprotective and antioxidant effect of Sphaeranthus indicus against acetaminopheninduced hepatotoxicity in rats. J Pharm Sci Res 2009Í¾1:2630.
Parmar KA and Patel AN. Preliminary Phytochemical Screening and study of antiviral activity and antibacterial activity of Tephrosia purpurea flower. Life sciences Leaflets. 2010;1:7-13.
Orhan I, Ozcelik B, Karaoglu T, Sener B. Antiviral and antimicrobial profiles of selected isoquinoline alkaloids from Fumaria and Corydalis species. Zeitschrift fur Naturforsch. 2007;62:19â€“26.
How to Cite
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.